(2026). PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure. Immunotherapy Advances.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"PD-1 Inhibitor-induced Rheumatic, Endocrine, and Sarcoidosis-like Immune-related Adverse Events in Metastatic Melanoma Are Associated with Improved Survival and Lower Corticosteroid Exposure."
Immunotherapy Advances 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"PD-1 Inhibitor-induced Rheumatic, Endocrine, and Sarcoidosis-like Immune-related Adverse Events in Metastatic Melanoma Are Associated with Improved Survival and Lower Corticosteroid Exposure."
Immunotherapy Advances, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.